Mya Tran, PharmD
Pharmacy School: Wayne State University
PGY1: Indiana University Health-Academic Health Center
PGY1: Mortality Outcomes among Critically Ill Patients with COVID-19 Who Received Tocilizumab
PGY2: Utility of Collecting Urine Cultures during Febrile Neutropenia Workup for Bone Marrow Transplant Recipients
During my PGY2 residency search, UNC's PGY2 oncology program stood out as it offers not only the opportunity for me to be clinically competent, but also to excel in research, academia, and to become a pharmacy leader. Coming from out of state, I have always been drawn to the progressive pharmacy model in North Carolina as I believe it offers a distinctively broad scope of practice that will maximize my experiences during residency. The UNC program collaboration with the NCI-designated North Carolina Cancer Center will expose me to a full spectrum of clinical complexities, innovative clinical trials, and various hematology/oncology sub-specialties where I would have the opportunity to learn from exceptional preceptors who are top experts in the field. The progressive research culture at UNC and its pattern of producing nationally recognized publications authored by pharmacists are also very appealing. Furthermore, the non-clinical elements of the PGY2 program, including teaching, presentation, and leadership training will also facilitate my development into a well-rounded, competent practitioner. Above all, I chose UNC because I was very impressed with the hospitality and supportive culture of the program. When talking to preceptors and current/past residents, I can tell that UNC is committed to offering the best training and I know I would get the best support and resources to make the most out of my PGY2 training.
Email Mya at Mya.Tran@unchealth.unc.edu